Retinitis Pigmentosa (RP) describes a heterogeneous group of retinopathies primarily involving photoreceptor degeneration (1) . Linkage studies have enabled the localisation of disease causing genes. Two RP genes have been mapped to Xp (2) . The first autosomal gene mapped to 3q, close to the gene encoding the photoreceptor cell specific pigment rhodopsin (1) . Mutations within the rhodopsin gene have now been implicated in both autosomal dominant (adRP) and autosomal recessive (arRP) forms of RP (1, 3) . More recently, an adRP gene has been localised to 6p, close to the gene encoding the photoreceptor protein peripherin/RDS (1) . Mutations in this gene have been shown to co-segregate with the disease phenotype in a number of adRP families (4) (5) (6) . Still further heterogeneity exists within adRP. It has been well established that there is an adRP locus at the pericentric region of chromosome 8 (7) . There is also weak evidence for the involvement of a second adRP gene on 3q (8) .
We have now identified a new rhodopsin mutation in the original family (TCDM1) used to localise the first adRP gene to 3q. Using heteroduplex analysis (9), we observed that heteroduplex DNA was present in only affected individuals in DNA fragments amplified from exon 3 of the rhodopsin gene. Direct genomic sequencing revealed that this was due to a T-G base change at codon 207, which results in the substitution of a methionine residue for an arginine residue. Using an allele specific oligonucleotide based assay, we established that the disease phenotype and the mutation were co-inherited ( Figure  1) , with a maximum Lod score of 17.7 at zero recombination (Table la) . We tested 100 normal unrelated individuals for the presence of this mutation and found that it was absent in all these controls.
This finding is of particular interest in view of weak evidence suggesting the possible involvement of a second adRP locus on 3q (8) . Using rhodopsin mutations in adRP families as highly polymorphic markers Inglehearn and colleagues observed 12% recombination (0 = 0.12, Z = 4.5) between the rhodopsin gene and the marker (D3S47) on 3q. They suggested that the presence of some families in which no rhodopsin mutations had been found but which showed tight linkage between adRP and D3S47 was consistent with the hypothesis that there may be a second adRP locus on 3q. Our recent identification of a rhodopsin mutation in TCDM1 must lend some doubt to the suggestion of two adRP loci on 3q, which was based on families such as this one.
The clinical presentation of adRP in the TCDM1 family is of particular interest due to the uncharacteristically early onset of the disease when compared to other well documented adRP patients (10) . Affected members exhibited onset of the disease within the first decade of life, diffuse funduscopic disturbances, and extinguished rod photoreceptor cell responses as assessed by ERGs. However ERG cone responses were retained until the third decade, although significantly reduced in amplitude and delayed in latency. Two colour dark adaptometry indicated a diffuse loss of rod and cone photoreceptor sensitivity with a greater involvement of rods and hence mirrored the electroretinographic findings.
The mutations observed within the rhodopsin gene and implicated in human inherited retinopathies have an extremely broad clinical spectrum. We can use previously constructed models of rhodopsin to speculate on the structure/function relationships of mutant rhodopsin molecules and hence possibly gain some insights into the underlying basis of the wide clinical spectrum observed in rhodopsin linked RP.
There is a considerable body of data from protein chemistry and site-directed mutagenesis which can be amalgamated to provide a crude representation of the 3-D structure of rhodopsin. Such approaches can never provide a detailed description of the conformation of the protein but they can augment our understanding of its structure and provide a model for investigating it's mechanisms of action. From such studies it is possible to speculate on the importance of the Met 207 -Arg substitution. There are two feasible scenarios. The first is that the methionine side-chain is exposed to the hydrophobic environment of the bilayer or is the interface between two transmembrane segments. Substitution by an arginine would seriously perturb folding either by destabilising the protein with a potentially charged residue to the hydrophobic phase or by a bulky polar residue at a helix-helix surface. An alignment of all rhodopsin sequences in this region indicates that Met 207 can be substituted by other hydrophobic residues and by Tyrosine (Table lb) . At first sight then, one could suppose that the residue is not critical to the intersegment contacts and could therefore be exposed to lipid.
An alternative explanation is illustrated in Figure 2 . This shows the position of the methionine side chain relative to the retinal models derived from theoretical considerations of hydrophobicity and conservation (Donnelly.D. and Blundell.T., unpublished) or from the modification of residue side-chains by hydrophillic and hydrophobic probes (11) . from the ring of retinal depending on the position of the chromophore. This does not necessarily imply that a significant interaction between the two occurs but it does suggest that there is not much scope to accommodate a bulky polar residue in this region without seriously perturbing the binding of the chromophore, leading in turn to an inactive receptor. It is perhaps relevant that the same position in the beta-adrenergic receptor is occupied by a serine residue, mutation of which affects the ability of the protein to interact with it's ligand (12) . The previous residue is also a serine and again substitution by alanine has a marked effect, this time on the folding of the polypeptide. Clearly this whole region is critical to the structure and activity of the protein and it is important to determine experimentally the effect of the Met 207-Arg substitution in human rhodopsin. The exact means by which mutant rhodopsins result in photoreceptor degeneration have still to be elucidated. To proceed from the level of observation of rhodopsin mutations in RP patients, to an understanding of the underlying basis of these retinopathies, it will be important to investigate the altered activities and the structure/function relationships of mutant proteins in detail. Previously developed models may serve to direct these studies. In turn, the observation of amino acid changes within the rhodopsin protein which have radical phenotypic effects in humans will provide valuable information for those updating models of the rhodopsin protein.
